Bone Biologics's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Bone Biologics (BBLG) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Bone Biologics vs Its Competitors
- Scale: Bone Biologics ranks #205 of 246 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.0% of industry market cap.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Bone Biologics's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Bone Biologics Corporation | - | - | - | No |
| Competitors combined (26) | ||||
| High-Confidence Competitors (3) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
BBLG Stock Performance relative to its Competitors
BBLG Stock Performance relative to High-Confidence Competitors
BBLG Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Adagio Medical Holdings inc | 282.9% | Outperformed |
| 2 | Monogram technologies inc | 282.9% | Outperformed |
| 3 | Orthopediatrics Corp | 282.9% | Outperformed |
| 4 | Tenon Medical Inc | 282.9% | Outperformed |
| 5 | Bioventus Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Bone Biologics's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Bone Biologics's Comment on Competition and Industry Peers
Publicly Traded Peers of Bone Biologics Corporation
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Bone Biologics Corporation |
1.50 | - |
 Medtronic Plc |
129,782.25 | 37,542.00 |
 Stryker Corp |
120,176.43 | 26,300.00 |
 Edwards Lifesciences Corporation |
61,110.08 | 6,512.50 |
 Zimmer Biomet Holdings Inc |
20,159.17 | 8,508.80 |
 Smith and Nephew Plc |
13,531.50 | 6,164.00 |
| SUBTOTAL | 371,783.97 | 98,383.11 |
Sign in to see all competitors of Bone Biologics Corporation.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Bone Biologics Corporation versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Bone Biologics's Competitors Named by the Company
Competitive relationships identified from Bone Biologics reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Stryker | Company report | 85% |
| Medtronic | Company report | 85% |
| DePuy-Synthes | Company report | 85% |
| Globus Medical | Company report | 85% |
| Zimmer-Biomet | Company report | 85% |
| Alphatec Holdings Inc | Company report | 85% |
| Orthofix Medical Inc | Company report | 85% |
| Conformis inc | Company report | 85% |
| Smith and Nephew Plc | Company report | 85% |
| Enovis Corp | Company report | 85% |
| Paragon 28 inc | Company report | 85% |
| Edwards Lifesciences Corporation | Company report | 85% |
| Si bone inc | Company report | 85% |
| Zimmer Biomet Holdings Inc | Company report | 85% |
| Encision Inc | Company report | 85% |
| Teleflex Incorporated | Company report | 85% |
| Sintx Technologies Inc | Company report | 85% |
| Integra Lifesciences Holdings Corp | Company report | 85% |
| Monogram technologies inc | Company report | 85% |
| Procept Biorobotics Corporation | Company report | 85% |
| Utah Medical Products Inc | Company report | 85% |
| Conmed Corporation | Company report | 85% |
| Nuvasive Inc | Company report | 85% |
| Surgalign Holdings Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Bone Biologics's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Bone Biologics's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Medtronic Plc | CARDIOVASCULAR 38.34 % |
| Stryker Corp | MedSurg and Neurotechnology 56.20 % |
| Edwards Lifesciences Corporation | United States 58.74 % |
| Zimmer Biomet Holdings Inc | Americas Segment 63.91 % |
| Globus Medical Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Bone Biologics Corporation.
Bone Biologics's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Bone Biologics Corporation | 1 | - | - |
| Medtronic Plc | 129,782 | 395,179 | 55,463 |
| Stryker Corp | 120,176 | 469,643 | 64,696 |
| Edwards Lifesciences Corporation | 61,110 | 407,031 | 62,725 |
| Zimmer Biomet Holdings Inc | 20,159 | 500,518 | 47,476 |
| Smith and Nephew Plc | 13,532 | 362,844 | 36,791 |
| PEERS TOTAL | 371,782 | 399,706 | 43,981 |
Sign in to see all peers for Bone Biologics Corporation.
Bone Biologics's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Medtronic Plc | United States 49.83 % |
| Stryker Corp | United States 75.92 % |
| Zimmer Biomet Holdings Inc | US 58.44 % |
| Globus Medical Inc | United States 81.31 % |
| Teleflex Incorporated | North America 35.23 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Bone Biologics Corporation.
Bone Biologics's Position in Industry Market Structure
Market-capitalization share and concentration across all 218 companies in Bone Biologics's industry classification, broader than the peer set above. Market cap in millions of $.Bone Biologics ranks #205 of 218 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 599, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 157,173 | 13.12 % |
| 2 | Medtronic Plc | 129,782 | 10.83 % |
| 3 | Stryker Corp | 120,583 | 10.06 % |
| 4 | 3m Company | 97,292 | 8.12 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 7 | Becton Dickinson And Company | 1,234 | 5.2% |
| 8 | Alcon inc | 1,234 | 5.2% |
| 9 | Resmed Inc | 1,234 | 5.2% |
| 10 | Medline Inc | 1,234 | 5.2% |
| 205 | Bone Biologics Corporation | 1 | 0.00 % |
Market cap and industry share for the rest of Bone Biologics's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-12.
Bone Biologics's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 200 | Adagio Medical Holdings inc | 1 | 156.31 % |
| 201 | Co diagnostics Inc | 1 | -97.88 % |
| 202 | Odyssey Health Inc | 1 | - |
| 203 | Mountain Crest Acquisition Corp V | 1 | - |
| 204 | Autonomix Medical Inc | 1,234 | 12.3% |
| 205 | Bone Biologics Corporation | 1 | -79.47 % |
| 206 | Nu med Plus Inc | 1,234 | 12.3% |
| 207 | Regentis Biomaterials Ltd | 1,234 | 12.3% |
| 208 | Encision Inc | 1,234 | 12.3% |
| 209 | Ir med Inc | 1,234 | 12.3% |
| 210 | Catheter Precision Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Bone Biologics's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-12. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Bone Biologics's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 37.0x | - |
| EV / EBITDA | - | 17.4x | - |
| P/B | 0.6x | 4.7x | -4.1x |
| Return on Equity | -57.06 % | industry aggregate | -71.55 % |
| Return on Invested Capital | -30.24 % | -6.49 % (avg) | -23.75 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Bone Biologics's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| Return on Invested Capital | - | - | - | - | -32.76 % | -169.61 % | -60.88 % | -30.95 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Bone Biologics's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Bone Biologics falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.9% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Bone Biologics's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 599 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Bone Biologics's dedicated Suppliers and Customers pages, not here.
Bone Biologics's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Bone Biologics falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Bone Biologics's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 71.6 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Bone Biologics's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Bone Biologics Corporation | 11.61 | 12.58 | - |
| Medtronic Plc | 0.15 | 2.10 | 0.57 |
| Stryker Corp | 0.50 | 2.08 | 0.65 |
| Edwards Lifesciences Corporation | 1.74 | 4.14 | 0.06 |
| Zimmer Biomet Holdings Inc | 0.25 | 1.93 | 0.60 |
| Smith and Nephew Plc | 0.35 | 2.57 | - |
Sign in to see all peers for Bone Biologics Corporation.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Bone Biologics's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Bone Biologics Corporation | Q3 2026 | - | - |
| Medtronic Plc | Q2 2026 | +13.7 % | +41.3 % |
| Stryker Corp | Q3 2026 | +7.6 % | -12.3 % |
| Edwards Lifesciences Corporation | Q2 2026 | +13.7 % | -27.2 % |
| Zimmer Biomet Holdings Inc | Q2 2026 | +4.8 % | +30.1 % |
| Smith and Nephew Plc | Q4 2025 | +6.1 % | +51.7 % |
| PEERS TOTAL | +7.5 % | +77.3 % |
Sign in to see all peers for Bone Biologics Corporation.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Bone Biologics's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Bone Biologics Corporation | Q3 2026 | - | - |
| Medtronic Plc | Q2 2026 | +13.8 % | -0.2 % |
| Stryker Corp | Q3 2026 | +3.0 % | +26.7 % |
| Edwards Lifesciences Corporation | Q2 2026 | +14.1 % | +35.7 % |
| Zimmer Biomet Holdings Inc | Q2 2026 | +7.3 % | +45.3 % |
| Smith and Nephew Plc | Q4 2025 | +6.2 % | - |
Sign in to see all peers for Bone Biologics Corporation.
Bone Biologics's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Bone Biologics Corporation | - | - | - |
| Medtronic Plc | 5.71% | 6.46% | 10.64% |
| Stryker Corp | 7.66% | 8.63% | 15.61% |
| Edwards Lifesciences Corporation | 7.41% | 8.39% | 9.65% |
| Zimmer Biomet Holdings Inc | 3.51% | 3.97% | 6.36% |
| Smith and Nephew Plc | 5.98% | 5.98% | 11.82% |
Sign in to see all peers for Bone Biologics Corporation.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Bone Biologics's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Bone Biologics Corporation | - | - |
| Medtronic Plc | 297.03 | 3.46 |
| Stryker Corp | 33.27 | 4.57 |
| Edwards Lifesciences Corporation | 60.91 | 9.38 |
| Zimmer Biomet Holdings Inc | 25.38 | 2.37 |
| Smith and Nephew Plc | 21.65 | 2.20 |
| PEERS AVERAGE | 34.35 | 3.78 |
Sign in to see all peers for Bone Biologics Corporation.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.